A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

被引：94
|
作者：
Wohl, David A. [1 ]
Cohen, Calvin [2 ]
Gallant, Joel E. [3 ]
Mills, Anthony [4 ]
Sax, Paul E. [5 ]
DeJesus, Edwin [6 ]
Zolopa, Andrew [7 ]
Liu, Hui C. [8 ]
Plummer, Andrew [8 ]
White, Kirsten L. [8 ]
Cheng, Andrew K. [8 ]
Rhee, Martin S. [8 ]
Szwarcberg, Javier [8 ]
机构：
[1] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27514 USA
[2] Community Res Initiat New England, Boston, MA USA
[3] Southwest Care Ctr, Santa Fe, NM USA
[4] Anthony Mills MD Inc, Los Angeles, CA USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA
[6] Orlando Immunol Ctr, Orlando, FL USA
[7] Stanford Univ, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA
[8] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2014年 / 65卷 / 03期
关键词：
CO-FORMULATED ELVITEGRAVIR; DOUBLE-BLIND; DISOPROXIL FUMARATE; PHASE-3; TRIAL;
D O I：
10.1097/QAI.0000000000000057
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E118 / E121
页数：5
相关论文
共 50 条
  • [41] A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
    Wohl, David
    Oka, Shinichi
    Clumeck, Nathan
    Clarke, Amanda
    Brinson, Cynthia
    Stephens, Jeffrey
    Tashima, Karen
    Arribas, Jose R.
    Rashbaum, Bruce
    Cheret, Antoine
    Brunetta, Jason
    Mussini, Cristina
    Tebas, Pablo
    Sax, Paul E.
    Cheng, Andrew
    Zhong, Lijie
    Callebaut, Christian
    Das, Moupali
    Fordyce, Marshall
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 58 - 64
  • [42] Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure
    Inciarte, A.
    Leal, L.
    Gonzalez, E.
    Leon, A.
    Lucero, C.
    Mallolas, J.
    Torres, B.
    Laguno, M.
    Rojas, J.
    Martinez-Rebollar, M.
    Gonzalez-Cordon, A.
    Cruceta, A.
    Arnaiz, J. A.
    Gatell, J. M.
    Garcia, F.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (10) : 2857 - 2861
  • [43] Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims
    Malinverni, Stefano
    Bedoret, Floriane
    Bartiaux, Magali
    Gilles, Christine
    De Wit, Stephane
    Libois, Agnes
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2021, 97 (05) : 329 - 333
  • [44] Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine
    Nadège Néant
    Florence Gattacceca
    Minh Patrick Lê
    Yazdan Yazdanpanah
    Catherine Dhiver
    Sylvie Bregigeon
    Saadia Mokhtari
    Gilles Peytavin
    Catherine Tamalet
    Diane Descamps
    Bruno Lacarelle
    Caroline Solas
    [J]. European Journal of Clinical Pharmacology, 2018, 74 : 473 - 481
  • [45] Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine
    Neant, Nadege
    Gattacceca, Florence
    Le, Minh Patrick
    Yazdanpanah, Yazdan
    Dhiver, Catherine
    Bregigeon, Sylvie
    Mokhtari, Saadia
    Peytavin, Gilles
    Tamalet, Catherine
    Descamps, Diane
    Lacarelle, Bruno
    Solas, Caroline
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (04) : 473 - 481
  • [46] Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)
    Ackaert, Oliver
    McDougall, David
    Perez-Ruixo, Carlos
    Perez-Ruixo, Juan Jose
    Jezorwski, John
    Crauwels, Herta M.
    [J]. AAPS JOURNAL, 2021, 23 (04):
  • [47] Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)
    Oliver Ackaert
    David McDougall
    Carlos Pérez-Ruixo
    Juan Jose Pérez-Ruixo
    John Jezorwski
    Herta M. Crauwels
    [J]. The AAPS Journal, 23
  • [48] Tenofovir/Emtricitabine plus Lopinavir/Ritonavir or Elvitegravir/cobicistat as a Single Tablet Regimen (STR) for PEP: A Randomized Clinical Trial
    Inciarte, Alexy
    Leal, Lorna
    Leon, Agathe
    Gonzalez, Eva
    Torres, Berta
    Lucero, Constanza
    Mallolas, Josep
    Laguno, Monserrat
    Rojas, Jhon
    Gatell, Josep
    Garcia, Felipe
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 389 - 389
  • [49] Simplification to Single Tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF from Multi-tablet Ritonavir-Boosted Protease Inhibitor Plus Coformulated Emtricitabine and Tenofovir DF Regimens: Week 96 Results of STRATEGY-PI (vol 18, pg 118, 2017)
    Doroana, Manuela
    [J]. HIV CLINICAL TRIALS, 2018, 19 (04): : 163 - 163
  • [50] PATIENT REPORTED OUTCOMES AFTER SIMPLIFICATION TO A SINGLE TABLET REGIMEN OF EFAVIRENZ (EFV)/EMTRICITABINE (FTC)/TENOFOVIR DF (TDF)
    Carlevari, M.
    Hodder, S.
    Mounzer, K.
    DeJesus, E.
    Maa, J-F
    Ebrahami, R.
    Grimm, K.
    Flaherty, J.
    Farajallah, A.
    [J]. INFECTION, 2009, 37 : 62 - 62
12345